Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Daiichi Sankyo to Shutter German Biotech Unit amid R&D Cost-Cut Drive
December 2, 2015
- Kyowa Kirin Launches Japan PIII Study for Regpara Successor
December 2, 2015
- Ole Moelskov Bech to Lead Novo Nordisk Japan from January
December 2, 2015
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
- Mitsubishi Tanabe Set to Derive 40% of Sales Abroad in FY2020, Shed 1,200 Jobs over 5 Years
December 1, 2015
- Chris Hourigan Named as New President of Janssen Japan Unit
December 1, 2015
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
- Eisai to Venture into Chinese Generic Market by Acquiring Local Firm
November 30, 2015
- Takeda’s MS Drug Copaxone Now Available; Actelion to Release Japan’s 1st Pediatric PAH Medicine in January
November 30, 2015
- JCR to Launch Cell Therapy for Post-Transplant Complication in February
November 30, 2015
- Viekirax Hits Japan Market, MHLW Orders Rare Label Revision upon Listing
November 27, 2015
- Eisai to Sell Food & Chemical Biz to Mitsubishi Chemical
November 27, 2015
- Sales of Candesartan AGs Miss Half-Year Target on Azilva Switches: ASKA Chief
November 26, 2015
- Japan’s 1st DTP-IPV Vaccine Containing Salk Vaccine to Be Available in December: Daiichi Sankyo
November 26, 2015
- Ex-Exec of Iwaki Subsidiary Embezzled 126 Million Yen
November 25, 2015
- Lilly Files Suit to Bar Launch of Sawai’s Evista Generic
November 24, 2015
- Eisai Gives Global Rights for Selective PDE4 Inhibitor E6005 to US Firm
November 24, 2015
- Kissei to License Endometriosis Treatment to Swiss Bioventure ObsEva
November 24, 2015
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…